Detalhe da pesquisa
1.
Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (TDF) Versus Efavirenz/Emtricitabine/TDF in Treatment-naive Adults With Human Immunodeficiency Virus Type 1 Infection: Week 96 Results of the Randomized, Double-blind, Phase 3 DRIVE-AHEAD Noninferiority Trial.
Clin Infect Dis
; 73(1): 33-42, 2021 07 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33336698
2.
Once-daily Doravirine for Initial Treatment of Adults Living With Human Immunodeficiency Virus-1: An Integrated Safety Analysis.
Clin Infect Dis
; 70(7): 1336-1343, 2020 03 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-31121013
3.
Pharmacokinetics, safety, and 48-week efficacy of oral raltegravir in HIV-1-infected children aged 2 through 18 years.
Clin Infect Dis
; 58(3): 413-22, 2014 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-24145879
4.
Safety and efficacy of doravirine as first-line therapy in adults with HIV-1: week 192 results from the open-label extensions of the DRIVE-FORWARD and DRIVE-AHEAD phase 3 trials.
Lancet HIV
; 11(2): e75-e85, 2024 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-38141637
5.
Pharmacokinetics, Tolerability, and Safety of Doravirine and Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate Fixed-Dose Combination Tablets in Adolescents Living With HIV: Week 24 Results From IMPAACT 2014.
J Acquir Immune Defic Syndr
; 92(2): 153-161, 2023 02 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36215957
6.
Efficacy, Safety, and Tolerability of Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate Fixed-Dose Combination Tablets in Adolescents Living With HIV: Results Through Week 96 from IMPAACT 2014.
J Pediatric Infect Dis Soc
; 12(12): 602-609, 2023 Dec 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-37815035
7.
Efficacy of raltegravir versus efavirenz when combined with tenofovir/emtricitabine in treatment-naïve HIV-1-infected patients: week-192 overall and subgroup analyses from STARTMRK.
HIV Clin Trials
; 13(4): 228-32, 2012.
Artigo
em Inglês
| MEDLINE | ID: mdl-22849964
8.
A Health Literate Patient-focused Approach to the Redesign of the Raltegravir (ISENTRESS) Pediatric Kit and Instructions for Use.
Pediatr Infect Dis J
; 41(1): 51-56, 2022 01 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34694252
9.
Long-term treatment with raltegravir or efavirenz combined with tenofovir/emtricitabine for treatment-naive human immunodeficiency virus-1-infected patients: 156-week results from STARTMRK.
Clin Infect Dis
; 53(8): 807-16, 2011 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-21921224
10.
Raltegravir with optimized background therapy for resistant HIV-1 infection.
N Engl J Med
; 359(4): 339-54, 2008 Jul 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-18650512
11.
Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection.
N Engl J Med
; 359(4): 355-65, 2008 Jul 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-18650513
12.
Design of a Phase III immunogenicity and safety study evaluating two-dose regimens of 9-valent human papillomavirus (9vHPV) vaccine with extended dosing intervals.
Contemp Clin Trials
; 105: 106403, 2021 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-33857679
13.
Efficacy, safety and central nervous system effects after switch from efavirenz/tenofovir/emtricitabine to doravirine/tenofovir/lamivudine.
AIDS
; 35(5): 759-767, 2021 04 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33587439
14.
Pharmacokinetics and Safety of a Raltegravir-Containing Regimen in Children Aged 4 Weeks to 2 Years Living With Human Immunodeficiency Virus and Receiving Rifampin for Tuberculosis.
J Pediatric Infect Dis Soc
; 10(2): 201-204, 2021 Mar 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-32448902
15.
Long-term efficacy and safety of Raltegravir combined with optimized background therapy in treatment-experienced patients with drug-resistant HIV infection: week 96 results of the BENCHMRK 1 and 2 Phase III trials.
Clin Infect Dis
; 50(4): 605-12, 2010 Feb 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-20085491
16.
Raltegravir (RAL) in Neonates: Dosing, Pharmacokinetics (PK), and Safety in HIV-1-Exposed Neonates at Risk of Infection (IMPAACT P1110).
J Acquir Immune Defic Syndr
; 84(1): 70-77, 2020 05 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31913995
17.
Impact of Low Birth Weight and Prematurity on Neonatal Raltegravir Pharmacokinetics: Impaact P1097.
J Acquir Immune Defic Syndr
; 85(5): 626-634, 2020 12 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-32925360
18.
Effects of omeprazole on plasma levels of raltegravir.
Clin Infect Dis
; 48(4): 489-92, 2009 Feb 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-19143531
19.
Use of Modeling and Simulations to Determine Raltegravir Dosing in Neonates: A Model for Safely and Efficiently Determining Appropriate Neonatal Dosing Regimens: IMPAACT P1110.
J Acquir Immune Defic Syndr
; 82(4): 392-398, 2019 12 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31658182
20.
Maternal-Neonatal Raltegravir Population Pharmacokinetics Modeling: Implications for Initial Neonatal Dosing.
CPT Pharmacometrics Syst Pharmacol
; 8(9): 643-653, 2019 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-31215170